Liquidia (LQDA)

Generated: May 16, 2026

Yellow Dot

Statistics

Metric	Value
Last Close	$56.93
Blended Price Target	42.62
Blended Margin of Safety	-25.1% Overvalued
Rule of 40 (Next)	62.1%
Rule of 40 (Current)	385.3%
FCF-ROIC	13.3%
Sales Growth Next Year	48.8%
Sales Growth Current Year	372.0%
Sales 3-Year Avg	157.0%
Industry	Drug Manufacturers - Specialty & Generic

Analysis

Liquidia now looks like a small but rapidly scaling commercial biopharma with a surprisingly durable core franchise, yet still meaningful execution and concentration risk. The launch of YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) has transformed the company from a royalty/settlement story into an integrated specialty pharma operator. Management reports YUTREPIA net product sales of $148.3 million for 2025, with $90.1 million in Q4 2025 alone, and more than 2,900 patients treated since launch in June 2025, driving the company’s second consecutive profitable quarter in Q4 2025 and continued profitability in Q1 2026 (Liquidia March 5, 2026 FY 2025 release; Liquidia May 11, 2026 Q1 2026 release).

The revenue base is relatively concentrated but has elements of durable, prescription‑driven recurrence given PAH’s chronic nature and the typical duration of inhaled treprostinil therapy. The economic moat is anchored in a combination of formulation IP, regulatory positioning, and demonstrated ability to compete head‑on with a well‑entrenched incumbent. However, the moat is not yet unassailable: payer pushback, competitive next‑generation therapies, and any safety or supply misstep could quickly erode share. Leadership has shown strong strategic persistence and capital discipline in navigating years of litigation, then pivoting rapidly into commercial scale‑up; whether this team can sustain operational excellence at a much larger scale remains the key test for long‑term business quality.

What the Company Does

Liquidia develops and commercializes therapies for pulmonary hypertension using its PRINT particle engineering platform. Its flagship product, YUTREPIA (inhaled treprostinil), is designed to treat PAH and PH‑ILD through a dry‑powder inhaler that aims to improve convenience and potentially tolerability versus nebulized competitors. The company also advances pipeline assets such as L606 for other cardiopulmonary indications.

Commercially, Liquidia now earns the majority of its revenue from direct net product sales of YUTREPIA in the U.S., following its mid‑2025 launch. The company previously derived income from collaborative arrangements and legal settlements, but those are now secondary. Management commentary and recent disclosures indicate that YUTREPIA accounts for the vast bulk of current revenue, with the pipeline still at the investment stage and not yet a material revenue contributor.

Revenue Recurrence & Predictability

Liquidia’s revenue model is prescription‑based rather than subscription, but the underlying indications create a quasi‑recurring pattern. PAH and PH‑ILD are chronic, progressive diseases; once a patient initiates an inhaled prostacyclin, they often remain on therapy long term unless efficacy or tolerability issues arise. As a result, underlying prescription cohorts can compound, giving some visibility as the in‑force patient base grows and refills accumulate.

That said, predictability is not as strong as in a classic contract or SaaS model. Patient starts and switches depend on specialist prescribing behavior, payer coverage dynamics, and competitive actions. Any guideline change, formulary decision, or safety concern could cause abrupt shifts. Revenue is therefore “recurring by disease biology” but still exposed to clinical, regulatory, and reimbursement shocks that can create volatility over short periods.

Revenue Growth Durability

The near‑term growth runway appears substantial. YUTREPIA only launched in mid‑2025, yet management reported more than 3,600 unique prescriptions and 2,900 patients treated by year‑end 2025 (Liquidia FY 2025 release). Given the multi‑year treatment horizon in PAH/PH‑ILD and the underpenetration of inhaled prostacyclins among eligible patients, Liquidia still seems early in its penetration curve. Additional growth levers include expanding prescriber adoption, broadening payer coverage, and deepening use within existing centers of excellence.

Longer term, growth durability will depend on pipeline execution and category dynamics. L606, which drove a $9.0 million increase in clinical expenses in 2025, signals an intent to build a broader pulmonary vascular portfolio. Structural tailwinds include aging populations, better diagnosis of pulmonary hypertension, and a trend toward combination and earlier‑stage therapy. Offsetting headwinds include potential entry of rival delivery technologies, generic pressure over time, and policy scrutiny of high‑cost specialty drugs, all of which could dampen growth beyond the current product cycle.

Economic Moat

Liquidia’s moat rests primarily on intangible assets and regulatory positioning rather than on scale or network effects. Its PRINT technology underpins differentiated particle engineering and delivery characteristics for treprostinil, protected by a portfolio of patents and know‑how. Years of litigation and regulatory maneuvering have produced a clearer competitive path for YUTREPIA versus nebulized and other inhaled treprostinil products, demonstrating both legal resilience and persistence. The early commercial traction suggests that physicians and patients value its dry‑powder profile.

However, the moat is still developing. Switching costs are moderate: patients can be transitioned between treprostinil formulations with careful titration, and payers have strong incentives to steer toward lower‑cost or rebated options. Larger competitors possess deeper commercial infrastructure and R&D resources that can pressure pricing or accelerate next‑generation alternatives. Whether Liquidia can broaden its IP base beyond a single main product and embed YUTREPIA as a default standard‑of‑care option will determine if its moat widens or remains narrow.

Management & Leadership

Liquidia is not currently founder‑led; its leadership has evolved from a platform‑focused early‑stage team to a commercially oriented specialist‑pharma management bench. The CEO and executive team have steered the company through an extended period of legal disputes and regulatory delays into a rapid commercial ramp, culminating in two consecutive profitable quarters by Q4 2025 and continued profitability in Q1 2026 (Liquidia FY 2025 and Q1 2026 releases). That track record suggests strong persistence and operational adaptability.

Detailed, current insider ownership data is not clearly disclosed in the recent press releases, but historically the company has had significant institutional and venture backing. Recent capital allocation choices have emphasized funding the YUTREPIA launch and advancing L606, while retaining a sizable cash balance of $190.7 million at the end of 2025 (Liquidia FY 2025 release). Management appears focused on reinvesting operating gains into pipeline and commercial expansion rather than heavy financial engineering.

Key Risks

The most immediate risk is product and indication concentration. YUTREPIA currently accounts for the majority of revenue and profit, leaving the company highly exposed to any safety signal, manufacturing disruption, or loss of reimbursement support. A negative label update, supply issue, or unfavorable payer decision could sharply reduce revenue while fixed commercial and R&D costs remain high.

Competitive and technological risk is also significant. Liquidia competes directly with established inhaled treprostinil products and other PAH therapies. Larger players can deploy larger sales forces, aggressive discounting, and lifecycle management strategies to defend share. Meanwhile, advances in gene therapy, oral combination regimens, or new mechanisms of action could eventually reduce reliance on inhaled prostacyclins, eroding YUTREPIA’s addressable market.

Finally, regulatory and legal risk remains a structural feature of this business. Any shift in FDA expectations, manufacturing standards, or post‑marketing requirements could impose new costs or delay pipeline assets like L606. Reimbursement reforms in specialty pharmacy or targeted drug‑pricing measures for high‑cost chronic therapies could compress margins or impede uptake. For a company still transitioning from a single‑asset story to a broader portfolio, these external shocks could have outsized impact.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of May 16, 2026 May 16, 2026